As bioactivity becomes increasingly central to regenerative dentistry, OsteoGen™ bone grafting materials are driving the conversation with Bioactive Crystal Technology (BCT), a non-sintered, biomimetic approach to bone regeneration. While many bone graft substitutes on the market today are sintered ceramics, BCT utilizes non-sintered calcium phosphate crystals with a composition similar to natural bone, providing a favorable environment for regeneration.
What is Bioactive Crystal Technology (BCT)?
Bioactive Crystal Technology (BCT) refers to the proprietary, non-sintered calcium phosphate crystals at the core of all OsteoGen bone grafting materials. Because these crystals are not subjected to the high-heat sintering process used in conventional ceramic grafts, they retain their bioactive properties, actively participating in the healing process by releasing calcium ions that support osteoblastic differentiation and mineralized matrix deposition. Rather than simply serving as a passive scaffold, BCT provides the necessary biochemical components for hard tissue regeneration, creating an environment that helps to promote cellular activity and bone formation. The result is a graft material that is biocompatible, osteoconductive, and truly bioactive.
Why Non-Sintered Matters
Sintering—the high-heat process used to manufacture many bone graft materials—fuses particles into dense, ceramic structures. While this achieves a usable particle size, it fundamentally alters the material's biological behavior. Sintered grafts often remain visible on radiographs indefinitely, which may make it difficult to assess true bone regeneration, and these dense graft materials can become encapsulated with connective tissue rather than being fully resorbed.
OsteoGen's non-sintered BCT takes a different path. The graft is radiolucent upon placement and gradually becomes radiopaque as it remodels into natural bone, typically within three to five months. This radiographic progression mirrors natural bone density changes, giving clinicians a clear, visual indicator of healing progress and optimal timing for implant placement.
"Bioactive Crystal Technology gives clinicians the best of both worlds: a graft material grounded in solid science that's also practical to use. It remodels like natural bone, and we can see that healing on a radiograph. That's the kind of predictability we need, and we get that from OsteoGen," states Charles D. Schlesinger, DDS, FICOI, VP of Clinical Development, Impladent Ltd.
Independent research published in the Journal of Periodontology validates OsteoGen's bioactive performance. Jones et al. found that OsteoGen® Plug achieved 94.4% porosity, creating an optimal scaffold environment for vascular infiltration and new bone formation, and demonstrated osteoblast proliferation up to 6 times greater than xenograft and allograft materials. Live cell imaging further confirmed significantly greater osteoblast activity across multiple time periods, while the xenograft material was unable to sustain cellular activity.
Simplified Workflow, Predictable Outcomes
OsteoGen™ bone grafting materials (available in Plug, Strip, and Block forms) combine BCT with Type I collagen to create ready-to-use grafting solutions. The OsteoGen® Plug, in particular, eliminates the need for a separate membrane in routine socket preservation cases, helping to streamline procedure time and simplify the surgical workflow without compromising clinical results.
About OsteoGen™
OsteoGen™ bone grafting materials, developed by Impladent Ltd., feature proprietary Bioactive Crystal Technology (BCT), consisting of non-sintered calcium phosphate crystals combined with Type I collagen. Available in Plug, Strip, and Block forms, OsteoGen™ products are designed to simplify grafting procedures while delivering predictable bone regeneration. Impladent Ltd. is recognized as a leader in the development of resorbable bone grafts, committed to regenerative solutions that meet clinician needs while prioritizing patient safety and comfort.
Source: www.osteogen.com
News 08 May 2026
Maria Gutierrez in Yorba Linda, California, has added the DEXIS Orthopantomograph OP 3D EX cone beam computed tomography (CBCT) system to its practice.
Products 23 February 2026
Next Generation Trident X-View 3D CBCT Product Line Now Available Through Mid America Dental Sales
The next generation Trident X-View 3D CBCT product line is now available through Mid America Dental Sales, a master distributor of dental technology. These advanced imaging systems from Italy are...
Products 22 December 2025
AI dental company announces 510(k) clearance from the U.S. Food and Drug Administration for Overjet CBCT Assist.
Products 24 September 2025
With top-of-the-line 3D imaging technology and all the essential dental imaging programs, Planmeca’s latest offering easily meets the everyday needs of general dentistry, endodontics, and...
Periodontology 10 September 2025
To update the findings of a systematic review from the year 2016 on the evidence for the accuracy and potential benefits of cone beam computed tomography (CBCT) in periodontal diagnostics.
Products 20 October 2026
News 20 October 2026
In recognition of National Dental Hygiene Month, Delta Dental highlights key findings from its 2026 State of America’s Oral Health and Wellness Report , a nationwide analysis of co
News 20 October 2026
Abra Health Group has launched The Dental Bank, a new community impact initiative designed to make essential oral health resources more accessible to individuals and families throu
Editorials 20 October 2026
Woman’s skull likely proof of ancient nose amputation, says College of Dentistry professor
Qian Wang, professor in biomedical sciences at Texas A&M College of Dentistry in Dallas, identified what he and other researchers believe is likely one of the first examples of an
Endodontics 20 October 2026
This peer-reviewed endodontics article summarizes clinical evidence from Clinical oral investigations (2026). It focuses on findings that may help dental professionals evaluate treatment decisions,...